Loading…
Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam
Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochem...
Saved in:
Published in: | Journal of feline medicine and surgery 2012-08, Vol.14 (8), p.527-533 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Request full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873 |
---|---|
cites | cdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873 |
container_end_page | 533 |
container_issue | 8 |
container_start_page | 527 |
container_title | Journal of feline medicine and surgery |
container_volume | 14 |
creator | Bommer, Nicholas X Hayes, Alison M Scase, Timothy J Gunn-Moore, Danièlle A |
description | Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days. |
doi_str_mv | 10.1177/1098612X12442041 |
format | article |
fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11104191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1098612X12442041</sage_id><sourcerecordid>1027041656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</originalsourceid><addsrcrecordid>eNqFUU1v1DAQjRCIlsKdE_KRAwHPJLGTE0IrvqRKvYDUm-U4k66rxF7spC2_hL_LrLasAAlxsUcz7z2_5ymK5yBfA2j9BmTXKsBLwLpGWcOD4hSaCkvUjXzINY_L_fykeJLztZSyqzp8XJwg1rKFWp8WPzaTD97ZSYxklzVRfiXymm78DbcWP1MWNgxic3FZwrFCQXc7hmYfg_BBOLtkceuXrViSDdkv3Ge6o4kPm5wPcbYijmLZkliTDzZ9F_1kh4ESU_hhGg78maZ4x3bmp8Wj0U6Znt3fZ8XXD--_bD6V5xcfP2_enZeuVu1Sdq6B0UKvlHZNpWjo0FLrqOkBtWyo7hT1ne6JA-sa3diOiFANWjejkq2uzoq3B93d2s80OAocYTK75Gc2aaL15s9J8FtzFW8MAPCHd8AKL-8VUvy2Ul7M7PM-ug0U12wQUbYKser-CwXJpmtQjWKoPEBdijknGo-WQJr97s3fu2fKi9-jHAm_ls2A8gDI9orMdVwTbyn_W_An2Pq4mw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1027041656</pqid></control><display><type>article</type><title>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</title><source>SAGE Open Access</source><creator>Bommer, Nicholas X ; Hayes, Alison M ; Scase, Timothy J ; Gunn-Moore, Danièlle A</creator><creatorcontrib>Bommer, Nicholas X ; Hayes, Alison M ; Scase, Timothy J ; Gunn-Moore, Danièlle A</creatorcontrib><description>Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.</description><identifier>ISSN: 1098-612X</identifier><identifier>ISSN: 1532-2750</identifier><identifier>EISSN: 1532-2750</identifier><identifier>DOI: 10.1177/1098612X12442041</identifier><identifier>PMID: 22408147</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; bladder ; carcinoma ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - mortality ; Carcinoma, Transitional Cell - veterinary ; Cat Diseases - drug therapy ; Cat Diseases - metabolism ; Cat Diseases - mortality ; Cats ; Cyclooxygenase 1 - drug effects ; Cyclooxygenase 1 - metabolism ; Cyclooxygenase 2 - drug effects ; Cyclooxygenase 2 - metabolism ; cystitis ; Female ; hematuria ; Immunochemistry ; immunohistochemistry ; Isoenzymes - antagonists & inhibitors ; Male ; medicine ; Meloxicam ; Neoplasm Proteins - metabolism ; Original ; surgery ; Survival Analysis ; Thiazines - administration & dosage ; Thiazines - pharmacology ; Thiazoles - administration & dosage ; Thiazoles - pharmacology ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - veterinary</subject><ispartof>Journal of feline medicine and surgery, 2012-08, Vol.14 (8), p.527-533</ispartof><rights>ISFM and AAFP 2012</rights><rights>ISFM and AAFP 2012 2012 International Society of Feline Medicine and American Association of Feline Practitioners</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</citedby><cites>FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104191/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104191/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,21947,27832,27903,27904,44924,45312,53769,53771</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1098612X12442041?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22408147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bommer, Nicholas X</creatorcontrib><creatorcontrib>Hayes, Alison M</creatorcontrib><creatorcontrib>Scase, Timothy J</creatorcontrib><creatorcontrib>Gunn-Moore, Danièlle A</creatorcontrib><title>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</title><title>Journal of feline medicine and surgery</title><addtitle>J Feline Med Surg</addtitle><description>Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.</description><subject>Animals</subject><subject>bladder</subject><subject>carcinoma</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - mortality</subject><subject>Carcinoma, Transitional Cell - veterinary</subject><subject>Cat Diseases - drug therapy</subject><subject>Cat Diseases - metabolism</subject><subject>Cat Diseases - mortality</subject><subject>Cats</subject><subject>Cyclooxygenase 1 - drug effects</subject><subject>Cyclooxygenase 1 - metabolism</subject><subject>Cyclooxygenase 2 - drug effects</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>cystitis</subject><subject>Female</subject><subject>hematuria</subject><subject>Immunochemistry</subject><subject>immunohistochemistry</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Male</subject><subject>medicine</subject><subject>Meloxicam</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Original</subject><subject>surgery</subject><subject>Survival Analysis</subject><subject>Thiazines - administration & dosage</subject><subject>Thiazines - pharmacology</subject><subject>Thiazoles - administration & dosage</subject><subject>Thiazoles - pharmacology</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - veterinary</subject><issn>1098-612X</issn><issn>1532-2750</issn><issn>1532-2750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFUU1v1DAQjRCIlsKdE_KRAwHPJLGTE0IrvqRKvYDUm-U4k66rxF7spC2_hL_LrLasAAlxsUcz7z2_5ymK5yBfA2j9BmTXKsBLwLpGWcOD4hSaCkvUjXzINY_L_fykeJLztZSyqzp8XJwg1rKFWp8WPzaTD97ZSYxklzVRfiXymm78DbcWP1MWNgxic3FZwrFCQXc7hmYfg_BBOLtkceuXrViSDdkv3Ge6o4kPm5wPcbYijmLZkliTDzZ9F_1kh4ESU_hhGg78maZ4x3bmp8Wj0U6Znt3fZ8XXD--_bD6V5xcfP2_enZeuVu1Sdq6B0UKvlHZNpWjo0FLrqOkBtWyo7hT1ne6JA-sa3diOiFANWjejkq2uzoq3B93d2s80OAocYTK75Gc2aaL15s9J8FtzFW8MAPCHd8AKL-8VUvy2Ul7M7PM-ug0U12wQUbYKser-CwXJpmtQjWKoPEBdijknGo-WQJr97s3fu2fKi9-jHAm_ls2A8gDI9orMdVwTbyn_W_An2Pq4mw</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Bommer, Nicholas X</creator><creator>Hayes, Alison M</creator><creator>Scase, Timothy J</creator><creator>Gunn-Moore, Danièlle A</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20120801</creationdate><title>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</title><author>Bommer, Nicholas X ; Hayes, Alison M ; Scase, Timothy J ; Gunn-Moore, Danièlle A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>bladder</topic><topic>carcinoma</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - mortality</topic><topic>Carcinoma, Transitional Cell - veterinary</topic><topic>Cat Diseases - drug therapy</topic><topic>Cat Diseases - metabolism</topic><topic>Cat Diseases - mortality</topic><topic>Cats</topic><topic>Cyclooxygenase 1 - drug effects</topic><topic>Cyclooxygenase 1 - metabolism</topic><topic>Cyclooxygenase 2 - drug effects</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>cystitis</topic><topic>Female</topic><topic>hematuria</topic><topic>Immunochemistry</topic><topic>immunohistochemistry</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Male</topic><topic>medicine</topic><topic>Meloxicam</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Original</topic><topic>surgery</topic><topic>Survival Analysis</topic><topic>Thiazines - administration & dosage</topic><topic>Thiazines - pharmacology</topic><topic>Thiazoles - administration & dosage</topic><topic>Thiazoles - pharmacology</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - veterinary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bommer, Nicholas X</creatorcontrib><creatorcontrib>Hayes, Alison M</creatorcontrib><creatorcontrib>Scase, Timothy J</creatorcontrib><creatorcontrib>Gunn-Moore, Danièlle A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of feline medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bommer, Nicholas X</au><au>Hayes, Alison M</au><au>Scase, Timothy J</au><au>Gunn-Moore, Danièlle A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</atitle><jtitle>Journal of feline medicine and surgery</jtitle><addtitle>J Feline Med Surg</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>14</volume><issue>8</issue><spage>527</spage><epage>533</epage><pages>527-533</pages><issn>1098-612X</issn><issn>1532-2750</issn><eissn>1532-2750</eissn><abstract>Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>22408147</pmid><doi>10.1177/1098612X12442041</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 1098-612X |
ispartof | Journal of feline medicine and surgery, 2012-08, Vol.14 (8), p.527-533 |
issn | 1098-612X 1532-2750 1532-2750 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11104191 |
source | SAGE Open Access |
subjects | Animals bladder carcinoma Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - metabolism Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - veterinary Cat Diseases - drug therapy Cat Diseases - metabolism Cat Diseases - mortality Cats Cyclooxygenase 1 - drug effects Cyclooxygenase 1 - metabolism Cyclooxygenase 2 - drug effects Cyclooxygenase 2 - metabolism cystitis Female hematuria Immunochemistry immunohistochemistry Isoenzymes - antagonists & inhibitors Male medicine Meloxicam Neoplasm Proteins - metabolism Original surgery Survival Analysis Thiazines - administration & dosage Thiazines - pharmacology Thiazoles - administration & dosage Thiazoles - pharmacology Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - veterinary |
title | Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20features,%20survival%20times%20and%20COX-1%20and%20COX-2%20expression%20in%20cats%20with%20transitional%20cell%20carcinoma%20of%20the%20urinary%20bladder%20treated%20with%20meloxicam&rft.jtitle=Journal%20of%20feline%20medicine%20and%20surgery&rft.au=Bommer,%20Nicholas%20X&rft.date=2012-08-01&rft.volume=14&rft.issue=8&rft.spage=527&rft.epage=533&rft.pages=527-533&rft.issn=1098-612X&rft.eissn=1532-2750&rft_id=info:doi/10.1177/1098612X12442041&rft_dat=%3Cproquest_AFRWT%3E1027041656%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1027041656&rft_id=info:pmid/22408147&rft_sage_id=10.1177_1098612X12442041&rfr_iscdi=true |